

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.
ON/4-32680A
APPLICATION NO.
10/530,856
APPLICANT
DEFFEZ ET AL.
FILING DATE
JANUARY 3, 2006Group
1615**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM						<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

/M.Y./	AR	Schiermeier S. Schmidt PC. "Fast dispersible ibuprofen tablets", Eur. J. Pharma Sci. April 15 (3), pp. 295-305 (2002)		
/M.Y./	AS	Methadone-Dispersible Tablet (methadose) MedicineNet.com. 2005		
/M.Y./	AT	"Loratadine Dispersible Tablet - Oral (Alavert, Claritin Reditabs)", Medicine Net.com (2005)		
EXAMINER		/Micah Paul Young/ (08/31/2009)	DATE CONSIDERED	08/31/2009

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.
DN4-32680A
APPLICATION NO.
10/530,856
APPLICANT
DEFJEZ ET AL.
FILING DATE
JANUARY 3, 2006Group
1615EXAMINER
INITIAL**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

/M.Y./	DA	Lamictal Dispersible, Patient Information Leaflet, GlaxoSmithKline (2007)
/M.Y./	DB	Augmentin Dispersible Tablets 375mg. Patient Information Leaflet, GlaxoSmithKline.2004
/M.Y./	DC	WHO Methods (annex) "Determination of Water Dispersible Tablet Disintegration Time" (1999)
/M.Y./	DD	Birnbaum et al. "Relative Bioavailability of Lamotrigine Chewable Dispersible Tablets Administered Rectally", MetScape Pharmacotherapy vol. 21, part 2, pp. 158-162 (2001)
/M.Y./	DE	Lamictal tablets, Chewable Dispersible Tablets, Prescribing Information, GlaxoSmithKline (2007)
/M.Y./	DF	Water Dispersible Tablets. 6.14, http://www.fao.org/ag/AGP/AGPP/Pesticid/specs/docs/WT.doc
/M.Y./	DG	Product search results for 'dispersible tablet': "Netnutri.com - New life colostrum 24 ounces", "Nature's Plus Vitamin A&D 10000/400 IU water dispersible", "Nature's Plus Vitamin A 10000 IU water dispersible - 90 tablets"
	DH	
	DI	
	DJ	
	DK	
	DL	
	DM	
	DN	

EXAMINER /Micah Paul Young/ (08/31/2009)

DATE CONSIDERED 08/31/2009

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.